









Markets
/
Stocks
/
nasdaq-arwr
/

Arrowhead Pharmaceuticals Inc

ARWR

38.000USD

+0.650+1.74%

Close 10/24, 16:00（ET）Quotes delayed by 15 min

5.25BMarket Cap

LossP/E TTM



Arrowhead Pharmaceuticals Inc

38.000

+0.650+1.74%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arrowhead Pharmaceuticals Inc

Currency: USD Updated: 2025-10-24

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arrowhead Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

36 / 501

Overall Ranking

122 / 4683

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 14 analysts

Buy

Current Rating

48.308

Target Price

+29.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Arrowhead Pharmaceuticals Inc Highlights

StrengthsRisks

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.55M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.55M.

Undervalued

The company’s latest PE is -31.39, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 107.84M shares, decreasing 9.12% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 477.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.43.

Financial Health

Currency: USD Updated: 2025-10-24

The company's current financial score is 7.97, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.97

Change



Financials

5.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.87

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.64

Key Metrics

Free cash flow

No Data

Arrowhead Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-24

The company’s current valuation score is 7.14, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -31.39, which is -91.47% below the recent high of -2.68 and -2.55% above the recent low of -32.19.

Score

Industry at a Glance

Previous score

7.14

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-24

The company’s current earnings forecast score is 7.71, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Arrowhead Pharmaceuticals Inc is 45.00, with a high of 80.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

7.71

Change

Support & Resistance

No Data

Analyst Rating

Based on 14 analysts

Buy

Current Rating

48.308

Target Price

+27.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

551

Total

Median

Average

Company name

Ratings

Analysts

Arrowhead Pharmaceuticals Inc

ARWR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-24

The company’s current price momentum score is 8.97, which is higher than the Biotechnology & Medical Research industry's average of 6.68. Sideways: Currently, the stock price is trading between the resistance level at 41.19 and the support level at 33.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.99

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.642

Neutral

RSI(14)

63.158

Neutral

STOCH(KDJ)(9,3,3)

56.079

Neutral

ATR(14)

1.767

High Vlolatility

CCI(14)

39.005

Neutral

Williams %R

40.306

Buy

TRIX(12,20)

0.932

Sell

StochRSI(14)

37.630

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

37.896

Buy

MA10

37.566

Buy

MA20

36.606

Buy

MA50

30.555

Buy

MA100

23.602

Buy

MA200

19.863

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-24

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 78.00%, representing a quarter-over-quarter decrease of 14.79%. The largest institutional shareholder is The Vanguard, holding a total of 15.50M shares, representing 11.21% of shares outstanding, with 14.73% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

17.60M

-3.23%

The Vanguard Group, Inc.

Star Investors

15.50M

+17.63%

Avoro Capital Advisors LLC

10.60M

-4.60%

State Street Investment Management (US)

6.37M

-8.98%

Slate Path Capital LP

5.23M

Fidelity Management & Research Company LLC

5.17M

+55.96%

Anzalone (Christopher Richard)

3.92M

-3.47%

Geode Capital Management, L.L.C.

2.98M

+0.96%

Invus Public Equities Advisors, LLC

2.67M

Marshall Wace LLP

2.16M

+3507.76%

Risk Assessment

Currency: USD Updated: 2025-10-24

The company’s current risk assessment score is 5.25, which is higher than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 1.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.